The COW Editorial Board is a select group of experts in the management of HIV and other viral infections. Dedicated to teaching practitioners who are actively involved in medical care for people with HIV or other viral infections, the COW Editorial Board ensures that the program remains a relevant and useful educational tool for the IAS–USA audience.

Members of the COW Editorial Board participate in a volunteer capacity. They are not compensated for their role in overseeing the program. Listed below are the COW Editorial Board members and their financial relationships with commercial interests within the past 12 months from the date of disclosure.


Editor-in-Chief

Michael S. Saag, MD
Professor of Medicine
University of Alabama at Birmingham
Birmingham, Alabama

Dr Saag has received research grants and support awarded to his institution from Gilead Sciences, Inc, Merck, and ViiV Healthcare. He has also served as a consultant for Gilead Sciences, Inc, Merck, and ViiV Healthcare. (Updated 08/06/18)


Coeditor

Marshall J. Glesby, MD, PhD
Professor of Medicine and Healthcare Policy and Research
Weill Cornell Medicine
New York, New York

Dr Glesby has received research support paid to his institution from Gilead Sciences, Inc. (Updated 06/28/2018)


Board Members

Judith A. Aberg, MD, FIDSA, FACP
George Baehr Professor of Medicine
ICAHN School of Medicine at Mount Sinai
New York, New York

Dr Aberg serves as a scientific advisor to Merck and has received research support paid to her institution from Bristol-Myers Squibb and Gilead Sciences, Inc. (Updated 02/17/17)

Roger J. Bedimo, MD, MS
Director of Infectious Disease Fellowship Training
University of Texas Southwestern Medical Center
Dallas, Texas

Dr Bedimo has received grants and research support awarded to the Veterans Affairs North Texas Healthcare System from Merck. He has served as a scientific advisor for Bristol-Myers Squibb, Merck, and Theratechnologies, Inc. (Updated 02/20/17)

Kara W. Chew, MD, MS
Assistant Clinical Professor of Medicine
University of California Los Angeles David Geffen School of Medicine
Los Angeles, California

Dr Chew has received research support awarded to the University of California Los Angeles from Gilead Sciences, Inc, and Merck. (Updated 02/16/17)

Steven C. Johnson, MD
Professor of Medicine
University of Colorado School of Medicine
Aurora, Colorado

Dr Johnson has served on an advisory board for ViiV Healthcare. (Updated 04/10/18)

Harry W. Lampiris, MD
Professor of Clinical Medicine
University of California San Francisco
San Francisco, California

Dr Lampiris has no relevant financial affiliations to disclose. (Updated 02/16/17)

Paul E. Sax, MD
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Dr Sax has served as a consultant or advisor to Gilead Sciences, Inc, Janssen Therapeutics, Merck, and GlaxoSmithKline/ViiV. He has received nonfinancial support from Bristol-Myers Squibb and grant support paid to his institution from Gilead Sciences, Inc, and GlaxoSmithKline/ViiV. (Updated 07/24/18)

David L. Wyles, MD
Chief of the Division of Infectious Diseases
Denver Health Medical Center
Denver, Colorado

Dr Wyles has received research grants awarded to his institution from AbbVie, Merck. Tacere, and Gilead Sciences, Inc, and has served as a consultant or advisor to AbbVie, Merck, and Gilead Sciences, Inc. (Updated 04/16/18)


Fellow Editor

Emily J. Cartwright, MD
Assistant Professor of Medicine
Emory University
Atlanta, Georgia

Dr Cartwright has received research grants awarded to Emory University from Bristol-Myers Squibb and Gilead Sciences, Inc. (Updated 02/16/17)


Staff of the Cases on the Web

Donna M. Jacobsen
Executive Director/President
International Antiviral Society–USA
San Francisco, California

Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 09/05/18)